Owen-lo 923 (Talk | contribs) |
Owen-lo 923 (Talk | contribs) |
||
Line 104: | Line 104: | ||
<blockquote> | <blockquote> | ||
− | <p style="text-align: justify;">The sequence of PhaR promoter is more properly selected in comparison with the previous parts. Previous publication: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570403/">Monitoring and kinetic analysis of the molecular interactions by which a repressor protein, PhaR, binds to target DNAs and poly[(R)-3-hydroxybutyrate] (2013) </a> is served as reference guideline and the selected functional promoter sequence is 134bp shorter than the previous part. The | + | <p style="text-align: justify;">The sequence of PhaR promoter is more properly selected in comparison with the previous parts. Previous publication: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570403/">Monitoring and kinetic analysis of the molecular interactions by which a repressor protein, PhaR, binds to target DNAs and poly[(R)-3-hydroxybutyrate] (2013) </a> is served as reference guideline and the selected functional promoter sequence is 134bp shorter than the previous part.</p> |
+ | <p style="text-align: justify;">The template sequence of PhaR is based on <a href="https://www.ncbi.nlm.nih.gov/nuccore/AM260479.1/">NCBI(AM260479.1)</a>, being 4bp difference to the previous part. </p> | ||
+ | <left><img src="https://static.igem.org/mediawiki/parts/8/88/T--Edinburgh_OG--Improve-image_2.jpeg" height="auto"></left> | ||
+ | <p style="text-align: justify;">Figure 1. Sequence alignment of NCBI(AM260479.1) and BBa_K108015. The 4bp difference is indicated by red color. </p> | ||
+ | <p style="text-align: justify;">The sequence is codon optimised to E.coli via IDT. <a href="http://parts.igem.org/Part:BBa_K2739000:Design">(See the Registry design page for the detail alignment) </a></p> | ||
</blockquote> | </blockquote> | ||
− | + | ||
</div> | </div> | ||
Line 126: | Line 130: | ||
<blockquote> | <blockquote> | ||
− | <p style="text-align: justify;">This composite part has allow us to investigate A) its relation in PHA production through PHA operon B) its function on PHA production with Phasin C) Assess the secretion function of Phasin-HlyA is compatible with phaR and if the improvement of phaR of PHA production is remained in this parts composition.</p> | + | <p style="text-align: justify;">This composite part has allow us to investigate A) its relation in PHA production through PHA operon; B) its function on PHA production with Phasin (BBa_K2739005); C) Assess the secretion function of Phasin-HlyA is compatible with phaR and if the improvement of phaR of PHA production is remained in this parts composition (BBa_K2739006);.</p> |
</blockquote> | </blockquote> | ||
<left><img src="https://static.igem.org/mediawiki/parts/3/3b/T--Edinburgh_OG--Improve-image_1.jpeg" height="auto"></left> | <left><img src="https://static.igem.org/mediawiki/parts/3/3b/T--Edinburgh_OG--Improve-image_1.jpeg" height="auto"></left> | ||
− | + | <p style="text-align: justify;">Figure 2. Diagram of other PhaR Biobricks development. </p> | |
</div> | </div> | ||
</div> | </div> |
Revision as of 22:53, 16 October 2018